Global Asthma Market Forecast 2034 Highlights Innovation and Biologic Growth
DelveInsight’s latest analysis projects robust expansion in the global asthma market through 2034, fueled by rising disease prevalence, heightened awareness, and continued therapeutic innovation. Major pharmaceutical and biotech players such as GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, and Genentech continue to shape a highly competitive and innovation-driven landscape.
The report, Asthma Market Insights, Epidemiology, and Market Forecast–2034, provides a detailed evaluation of disease burden, historical data, and projected market performance across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. It delivers forward-looking insights into treatment evolution, drug uptake trends, and commercial opportunities.
To Know in detail about the Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here: Asthma Market Forecast
In 2023, the asthma market across the seven major markets (7MM) was valued at approximately USD 19 billion and is anticipated to grow at a CAGR of nearly 3.9% between 2024 and 2034. Growth is supported by increasing diagnosis rates, expanding biologic adoption, and the introduction of next-generation targeted therapies.
In May 2025, AstraZeneca reported that its triple-combination therapy Breztri Aerosphere met primary endpoints in the Phase III KALOS and LOGOS trials. The therapy demonstrated statistically significant and clinically meaningful improvements in lung function compared with dual ICS/LABA regimens among 4,434 patients with uncontrolled asthma, reinforcing its potential role in advanced treatment settings.
Earlier in 2025, Enveda Biosciences expanded its lead program ENV-294 into asthma after initial development in atopic dermatitis, highlighting the growing application of AI-driven drug discovery in respiratory inflammation. In 2024, Kinaset Therapeutics showcased clinical data on frevecitinib (KN-002) for moderate-to-severe asthma and COPD at the European Respiratory Society Congress.
The United Kingdom represented the largest asthma market among EU countries in 2023, while Spain recorded the smallest share. Scientific dialogue at major congresses such as the American Thoracic Society meeting has emphasized advancements in biomarkers, pediatric asthma care, inhaled JAK inhibitors, and oral STAT6 degraders.
Patent dynamics are also shaping the landscape. XOLAIR’s syringe formulation patent protection in the U.S. and Europe is expected to expire between 2024 and 2025, though no generic competition has yet emerged. CINQAIR retains U.S. biologic exclusivity through 2028 and European regulatory exclusivity through 2026.
Epidemiologically, asthma remains one of the most prevalent chronic respiratory diseases worldwide. Across the 7MM, diagnosed prevalent cases were estimated at approximately 55 million in 2022, with adults representing the largest segment. According to the World Health Organization, asthma affected around 262 million people globally in 2019 and caused approximately 455,000 deaths, making it the most common chronic disease in children.
The epidemiology analysis within the report covers total prevalence, severity-based segmentation, gender distribution, and episodic versus chronic diagnosed cases across the seven major markets between 2020 and 2034.
Download the report to understand which factors are driving Asthma epidemiology trends @ Asthma Epidemiology Forecast
Beyond Western pharmaceutical leaders, Asian innovation is playing an increasingly strategic role in asthma biologics and immunomodulatory therapies.
In Japan, Kyowa Kirin Co., Ltd. has been instrumental in advancing IL-5 biology through its antibody platform. The company originated benralizumab (Fasenra), later licensed to AstraZeneca, which targets IL-5 receptor-α and induces antibody-dependent cellular cytotoxicity, leading to eosinophil depletion rather than simple cytokine blockade. This mechanism has demonstrated strong exacerbation reduction in severe eosinophilic asthma and represents a milestone in biologic therapy development.
Kyorin Pharmaceutical Co., Ltd. and Taiho Pharmaceutical (part of the Otsuka group) have historically developed suplatast tosilate (IPD-1151T), a Th2 cytokine inhibitor that suppresses IL-4 and IL-5 production, thereby reducing IgE levels and eosinophilic inflammation. The therapy remains recognized in Japan as an anti-allergy and asthma treatment and continues to be evaluated in combination and investigator-led studies across Asia.
As a member of the Roche Group, Chugai Pharmaceutical Co., Ltd. is active in antibody engineering and exploratory anti-TSLP and upstream cytokine pathway research, targeting epithelial-driven inflammation upstream of IL-5 and IL-13 signaling. Meanwhile, Sosei Heptares is investigating GPCR modulators such as muscarinic receptor-targeted candidates as potential non-steroidal anti-inflammatory approaches in respiratory disease.
South Korea has also emerged as a significant contributor. Hanmi Pharmaceutical Co., Ltd. is developing long-acting cytokine fusion biologics and CRTH2 antagonists aimed at modulating T-cell regulation and reducing eosinophil recruitment through prostaglandin D2 receptor inhibition. Yuhan Corporation is advancing YH35324, a next-generation anti-IgE antibody designed to prevent allergic mast-cell activation.
Drug delivery innovation is another focal point, with Alteogen Inc. entering licensing agreements with AstraZeneca to enable subcutaneous biologic administration using recombinant hyaluronidase technology. Biosimilar development is being pursued by Samsung Bioepis, which is conducting Phase 1–3 studies on monoclonal antibodies targeting IgE and IL-5 pathways to improve cost accessibility. Additionally, HK inno.N and LigaChem Biosciences are investigating CRTH2 antagonist small molecules as oral alternatives to injectable biologics.
In Taiwan, companies such as Oneness Biotech Co., Ltd. are advancing FB825, an anti-IL-17 pathway biologic in Phase 2 studies for allergic airway disease. United BioPharma is developing anti-IgE and cytokine-targeting biologics, while Medigen Biotechnology is exploring immune tolerance–modulating protein biologics in early respiratory research.
Across Asia-originated programs, key mechanistic targets include IL-5/IL-5R (eosinophil survival), IL-4/IL-13 (IgE switching and mucus production), TSLP (upstream epithelial inflammation), IgE (allergic activation), and CRTH2 (eosinophil recruitment). These pathways mirror global innovation trends and reinforce Asia’s growing role in shaping the biologic asthma market.
The report further evaluates drug uptake patterns, patient adoption rates, and comparative market share analyses for emerging therapies including GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, and SB010.
Discover more about therapies set to grab major Asthma market share @ Asthma Treatment Landscape
With a strong and diversified pipeline targeting multiple pathogenic mechanisms, alongside flexible formulation strategies and convenient dosing options, the asthma market is positioned for sustained transformation. Expanding patient populations and the anticipated launch of innovative biologics and small-molecule therapies are expected to significantly reshape competitive dynamics through 2034.
To know more about Asthma companies working in the treatment market, visit @ Asthma Clinical Trials and Therapeutic Assessment
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Related report
Asthma - Epidemiology Forecast - 2034
DelveInsight’s “Asthma – Epidemiology Forecast – 2034” report delivers an in-depth understanding of the asthma, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The leading Asthma Companies developing therapies include GlaxoSmithKline, AstraZeneca, Novartis, Sanofi, Teva Pharmaceuticals, Boehringer Ingelheim, and others.
Asthma - Pipeline Insight, 2026
DelveInsight’s, “Asthma - Pipeline Insight, 2026,” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Asthma pipeline landscape. The leading Asthma Companies developing therapies include GlaxoSmithKline, AstraZeneca, Novartis, Sanofi, Teva Pharmaceuticals, Boehringer Ingelheim, and others.
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: abhishek@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com